Orion
54
EUR
+0.86 %
13,943 following
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
+0.86%
+3.05%
+26.23%
+21.87%
+11.78%
+50.21%
+38.71%
+56.11%
+380.85%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Read moreMarket cap
7.62B EUR
Turnover
8.97M EUR
P/E (adj.) (25e)
23.11
EV/EBIT (adj.) (25e)
18.13
P/B (25e)
6.89
EV/S (25e)
4.67
Dividend yield-% (25e)
3.15 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
3/4
2025
General meeting '25
4/4
2025
Half year dividend
23/4
2025
Interim report Q1'25
Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion and Aiforia extend collaboration to preclinical study evaluations
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Managers’ transactions – Outi Vaarala
Orion Corporation: Managers’ transactions – Niclas Lindstedt
Orion Corporation: Managers’ transactions – Hao Pan
Orion Corporation: Managers’ transactions – Satu Ahomäki
